MK-677 vs Survodutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both MK-677 and Survodutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
MK-677 Survodutide
Weight 624.77 Da ~4,500 Da
Half-life ~24 hours Approximately 6 days (109-115 hours)
Chain — 29 amino acids
Type Non-peptide ghrelin receptor agonist Peptide with fatty acid acylation
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
MK-677 Survodutide
Status Well Studied Extensively Studied
References 7 studies 3 studies
Latest July 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.